Mycobacterial infections can be challenging to diagnose because clinically relevant species differ in their clinical and therapeutic implications, while closely related species, strain-level variation and mixed infections can complicate conventional testing. Nontuberculous mycobacteria (NTM) have also received increasing attention as important causes of pulmonary disease. Although culture, mass spectrometry and molecular assays provide important diagnostic options, there remains a need for approaches that can combine broad detection with species-level identification and multiplex analysis.
In a new commentary published in LabMed Discovery, Professor Dakang Xu and colleagues from Shanghai Jiao Tong University School of Medicine discuss the clinical and technological potential of a CRISPR-assisted nanodroplet platform, termed CRISPR-Assisted Nanodroplet-pairing Platform for Differential Identification of NTM (CANDI). The commentary analyzes the platform originally developed by Gou and colleagues and published in Science Translational Medicine, highlighting its ability to combine broad-range amplification, species-specific CRISPR recognition, fluorescence encoding, and microfluidic droplet pairing within a single diagnostic architecture.
A key feature of the platform is its genome-informed design. The development of CANDI involved analysis of 103,332 Mycobacterium genomes to identify highly conserved regions within the 16S and 23S rRNA genes for broad-range amplification. Species-specific guide RNAs were then selected according to sequence differences between species while also considering sequence conservation within individual target species. This strategy is designed to provide broad target coverage while maintaining species-level specificity and reducing the risk of missed detection associated with strain-level sequence variation.
The commentary also highlights the platform's ability to analyze mixed samples. CANDI can simultaneously identify multiple mycobacterial species and was demonstrated to resolve mixtures containing up to five species, including closely related organisms. In clinical evaluation, the platform also detected some organisms that were not recovered by culture. The authors note that these additional molecular detections may reflect the analytical sensitivity of direct molecular testing or the presence of low-abundance organisms that are difficult to recover by culture. This capability may be particularly relevant for slow-growing or low-abundance mycobacteria in mixed infections, where conventional culture-based approaches may have difficulty recovering less abundant organisms.
Beyond mycobacterial diagnosis, the commentary discusses a broader design principle for multiplex molecular diagnostics. By separating amplification, molecular recognition, signal identity, and spatial organization, CANDI reduces the dependence on increasingly complex multiplex primer designs and provides an alternative framework for scalable molecular detection.
The authors also emphasize that further development is needed before CANDI can be integrated into routine clinical laboratories. Important challenges include addressing genomic variation, interpreting low-abundance culture-independent detections in clinical context, and automating droplet generation, pairing, imaging and computational analysis. Future development toward a standardized sample-to-answer workflow will be important for translating this type of multiplex molecular technology into clinical practice.
